Insulet Corporation (PODD)
Insulet Corporation is a Healthcare company in the S&P 500, with a market capitalization of about $9.1 billion as of October 1, 2026.
- Ticker
- PODD · Nasdaq
- Sector
- Healthcare
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus
- Market cap
- $9.1 billion
- Employees
- 5,400
- Headquarters
- Acton, MA
- Fiscal year end
- December 31
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Financial statements
Nvevo shows Insulet Corporation's income statement, balance sheet, cash flow statement and key ratios as reported in its 10-K and 10-Q filings with the SEC, annually and quarterly, alongside price history, recent news and fair value models.
Other Healthcare companies
- Eli Lilly and Company (LLY)
- Johnson & Johnson (JNJ)
- AbbVie Inc. (ABBV)
- Merck & Co., Inc. (MRK)
- UnitedHealth Group Incorporated (UNH)
- Thermo Fisher Scientific Inc. (TMO)
- Amgen Inc. (AMGN)
- Gilead Sciences, Inc. (GILD)
Research another company · Market map · Stock screener · Compare companies